Got­tlieb con­tin­ues to be Trump's lead­ing can­di­date for FDA; Be­yond­Spring com­pletes un­usu­al IPO

→ Scott Got­tlieb is Pres­i­dent Trump’s lead­ing choice for FDA com­mis­sion­er, Bloomberg now re­ports, cit­ing “peo­ple” fa­mil­iar with the mat­ter. Bio­Cen­tu­ry had the scoop in mid-Feb­ru­ary.

→ Be­yond­Spring, a biotech with deep roots in Chi­na, has com­plet­ed an un­usu­al IPO this week. Af­ter ini­tial­ly tar­get­ing an of­fer­ing de­signed to raise $100 mil­lion, the biotech end­ed up sell­ing 174,286 shares at $20 and then ex­e­cut­ed a pri­vate of­fer­ing to in­sid­ers for an­oth­er 2.5 mil­lion shares. The to­tal amount­ed to $54 mil­lion. The com­pa­ny has a can­cer drug in sev­er­al stud­ies.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.